March Biosciences, Inc is a Houston-based clinical-stage cell therapy company with a mission to address relapsed and recurrent T-cell lymphoma, an orphan indication with few treatment options and extremely poor patient outcomes. Despite the clear success of chimeric antigen receptor (CAR) T-cell therapy in B-cell lymphoma and leukemia, no CAR T-cell therapies are approved for T-cell cancers due to the risk of toxicity for normal T-cells, leading to catastrophic immunodeficiency. The scientific founders of March Biosciences have developed and optimized a CD5-directed CAR T-cell therapy, MB-105, currently in a Phase 1 trial at Baylor College of Medicine. Early trial results have shown a favora...

Read More

March Biosciences, Inc is a Houston-based clinical-stage cell therapy company with a mission to address relapsed and recurrent T-cell lymphoma, an orphan indication with few treatment options and extremely poor patient outcomes. Despite the clear success of chimeric antigen receptor (CAR) T-cell therapy in B-cell lymphoma and leukemia, no CAR T-cell therapies are approved for T-cell cancers due to the risk of toxicity for normal T-cells, leading to catastrophic immunodeficiency. The scientific founders of March Biosciences have developed and optimized a CD5-directed CAR T-cell therapy, MB-105, currently in a Phase 1 trial at Baylor College of Medicine. Early trial results have shown a favorable safety profile and robust efficacy in both T-cell lymphoma and leukemia patients, with multiple complete remissions and long-term survivors. March Biosciences is continuing development to make this therapy broadly accessible to patients and has assembled an experienced team of cell therapy scientists, clinicians, and industry professionals and established key institutional partnerships in Houston, Texas to further develop MB-105. With CPRIT's support, March Biosciences will prepare for a company-sponsored IND and advance MB-105 to a Phase 2 trial to broaden patient access and advance towards full commercialization of this therapy.

Read Less